Fortress Biotech, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
Fortress Biotech, Inc. (FBIO) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of $1.19 million for the 12-month period ending 2020-12-31, per its 10-K/A filed 2021-04-09.
Discontinued › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2021-04-09
- Fortress Biotech, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2018-12-31 was $463.00K.
- Fortress Biotech, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2018-09-30 was $84.00K, a 13.51% increase year-over-year.
- Fortress Biotech, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2018-06-30 was $140.00K, a 25.53% decline year-over-year.
- Fortress Biotech, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2018-03-31 was -$250.00K, a 357.73% decline year-over-year.
- Fortress Biotech, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2020 was $1.19M.
- Fortress Biotech, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2018 was $437.00K.
- Fortress Biotech, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2017 was -$457.00K, a 685.90% decline from fiscal 2016.
- Fortress Biotech, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2016 was $78.00K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month as first filed |
|---|---|---|---|---|---|
| 2020-12-31 | $1.19M 10-K/A · filed 2021-04-09 | ||||
| 2018-12-31 | $463.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $547.00K derived: sum of 2 quarters · filed 2020-03-16 | $687.00K derived: sum of 3 quarters · filed 2020-03-16 | $437.00K 10-K · filed 2020-03-16 | |
| 2018-09-30 | $84.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $224.00K derived: sum of 2 quarters · filed 2018-11-09 | -$26.00K 10-Q · filed 2018-11-09 | -$842.00K derived: sum of 4 quarters · filed 2019-03-18 | |
| 2018-06-30 | $140.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | -$110.00K 10-Q · filed 2018-08-09 | -$926.00K derived: sum of 3 quarters · filed 2019-03-18 | -$852.00K derived: sum of 4 quarters · filed 2019-03-18 | |
| 2018-03-31 | -$250.00K 10-Q · filed 2018-05-10 | -$1.07M derived: sum of 2 quarters · filed 2019-03-18 | -$992.00K derived: sum of 3 quarters · filed 2019-03-18 | -$804.00K derived: sum of 4 quarters · filed 2019-03-18 | |
| 2017-12-31 | -$816.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | -$742.00K derived: sum of 2 quarters · filed 2019-03-18 | -$554.00K derived: sum of 3 quarters · filed 2019-03-18 | -$457.00K 10-K · filed 2019-03-18 | $457.00K 10-K · filed 2018-03-16 |
| 2017-09-30 | $74.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $262.00K derived: sum of 2 quarters · filed 2017-11-09 | $359.00K 10-Q · filed 2017-11-09 | $424.00K derived: sum of 4 quarters · filed 2018-03-16 | |
| 2017-06-30 | $188.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $285.00K 10-Q · filed 2017-08-09 | $350.00K derived: sum of 3 quarters · filed 2018-03-16 | ||
| 2017-03-31 | $97.00K 10-Q · filed 2017-05-10 | $162.00K derived: sum of 2 quarters · filed 2018-03-16 | |||
| 2016-12-31 | $65.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $78.00K 10-K · filed 2018-03-16 | |||
| 2016-09-30 | $13.00K 10-Q · filed 2016-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |